Ligand Pharmaceuticals
LGND
#4204
Rank
$2.08 B
Marketcap
$108.15
Share price
-1.15%
Change (1 day)
48.23%
Change (1 year)

P/E ratio for Ligand Pharmaceuticals (LGND)

P/E ratio as of March 2025 (TTM): 69.7

According to Ligand Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 69.7293. At the end of 2022 the company had a P/E ratio of -33.7.

P/E ratio history for Ligand Pharmaceuticals from 2001 to 2023

20052010201520202025200000000000000000400000000000000000600000000000000000800000000000000000100000000000000000012000000000000000000companiesmarketcap.com

PE ratio at the end of each year

Year P/E ratio Change
2022-33.7-221.14%
202127.8-106.28%
2020-443-20949.58%
20192.13-83.05%
201812.5-91.19%
2017142-122.46%
2016-634-10933.9%
20155.85-89.6%
201456.3-3.98%
201358.6-100%
2012> 10001.2338542617679E+19%
201115.1-241.22%
2010-10.7-89.43%
2009-1016002.71%
2008-1.66-255.32%
20071.07-106.41%
2006-16.714.97%
2005-14.521.73%
2004-11.976.66%
2003-6.7450.86%
2002-4.47-70.8%
2001-15.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
22.1-68.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-2.86-104.10%๐Ÿ‡บ๐Ÿ‡ธ USA
11.3-83.87%๐Ÿ‡ฌ๐Ÿ‡ง UK
51.5-26.12%๐Ÿ‡บ๐Ÿ‡ธ USA
14.0-79.86%๐Ÿ‡บ๐Ÿ‡ธ USA
155 122.29%๐Ÿ‡บ๐Ÿ‡ธ USA
15.3-78.06%๐Ÿ‡บ๐Ÿ‡ธ USA
6.47-90.72%๐Ÿ‡บ๐Ÿ‡ธ USA
11.6-83.41%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.